Identification of broadly reactive DR restricted epitopes
AssigneeEpimmune Inc.
InventorsAlessandro Sette, John Sidney, Scott Southwood
Life of this patent
Estimating the term…
Abstract
The present invention is based on peptide binding specificities of HLA DR4w4, DR1 and DR7. Peptides binding to these DR molecules have a motif characterized by a large aromatic or hydrophobic residue in position 1 (Y, F, W, L, I, V, M) and a small, non charged residue in position 6 (S, T, C, A, P, V, I, L, M). In addition, allele-specific secondary effects and secondary anchors are defined, and these results were utilized to derive allele specific algorithms. By the combined use of such algorithms peptides capable of degenerate DR1, 4, 7 binding were identified.
Claims2
A method to screen peptides to distinguish candidate peptides for administration as an immunogen from peptides that are not candidate peptides for administration as an immunogen which method comprises
- (a) providing at least one peptide that bears a DR motif corresponding to a Class II HLA molecule;
- (b) testing the peptide for binding affinity to a Class II HLA DR molecule, whereupon IC50 binding affinity in nanomolar (nM) is determined;
- (c) comparing the binding affinity of the peptide to an IC50 affinity threshold of 1,000 nM;
- and
- (d) identifying as a candidate peptide for administration as an immunogen a peptide that binds said class II HLA DR molecule at an IC50 of <1,000 nM, and identifying as a peptide not a candidate for administration as an immunogen, a peptide that binds said Class II HLA DR molecule at an IC50 of >1,000 nM,
- thereby distinguishing candidate peptides for administration as immunogens from peptides not candidates for administration as immunogens.
A method to screen peptides to distinguish peptides which are T cell epitopes in the context of a DR molecule from peptides that are non T cell epitopes in the context of a DR molecule which method comprises
- (a) providing at least one peptide that bears a DR motif corresponding to a Class II HLA molecule;
- (b) testing the peptide for binding affinity to a Class II HLA DR molecule, whereupon IC50 binding affinity in nanomolar (nM) is determined;
- (c) comparing the binding affinity of the peptide to an IC50 affinity threshold of 1,000 nM;
- and
- (d) identifying as a T cell epitope that binds said Class II HLA DR molecule at an IC50 of >1,000 nM, and identifying as not a T cell epitope a peptide that binds said Class II HLA DR molecule at an IC50 of >1,000 nM,
- thereby distinguishing peptides that are T cell epitopes from peptides that are not T cell epitopes.
Dependencies are inferred from the claim text.